GB835638A
(en)
|
1956-12-01 |
1960-05-25 |
Novo Terapeutisk Labor As |
Insulin crystal suspensions having a protracted effect
|
GB840870A
(en)
|
1957-08-03 |
1960-07-13 |
Novo Terapeutisk Labor As |
Improvements in or relating to insulin preparations
|
US3984696A
(en)
|
1974-12-11 |
1976-10-05 |
Medi-Ray, Inc. |
Radiation guard for X-ray table
|
JPS6033474B2
(ja)
|
1978-05-11 |
1985-08-02 |
藤沢薬品工業株式会社 |
新規なヒアルロニダ−ゼbmp−8231およびその製造法
|
PH25772A
(en)
|
1985-08-30 |
1991-10-18 |
Novo Industri As |
Insulin analogues, process for their preparation
|
CA1275922C
(en)
|
1985-11-28 |
1990-11-06 |
Harunobu Amagase |
Treatment of cancer
|
US5614492A
(en)
|
1986-05-05 |
1997-03-25 |
The General Hospital Corporation |
Insulinotropic hormone GLP-1 (7-36) and uses thereof
|
DK257988D0
(da)
|
1988-05-11 |
1988-05-11 |
Novo Industri As |
Nye peptider
|
US4923162A
(en)
|
1988-09-19 |
1990-05-08 |
Fleming Matthew C |
Radiation shield swivel mount
|
DE3837825A1
(de)
|
1988-11-08 |
1990-05-10 |
Hoechst Ag |
Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
|
HUT56857A
(en)
|
1988-12-23 |
1991-10-28 |
Novo Nordisk As |
Human insulin analogues
|
NZ232375A
(en)
|
1989-02-09 |
1992-04-28 |
Lilly Co Eli |
Insulin analogues modified at b29
|
EP0471036B2
(en)
|
1989-05-04 |
2004-06-23 |
Southern Research Institute |
Encapsulation process
|
US5006718A
(en)
|
1989-07-21 |
1991-04-09 |
Lenhart Mark J |
X-ray shield for X-ray examination table
|
US5545618A
(en)
|
1990-01-24 |
1996-08-13 |
Buckley; Douglas I. |
GLP-1 analogs useful for diabetes treatment
|
DK155690D0
(da)
|
1990-06-28 |
1990-06-28 |
Novo Nordisk As |
Nye peptider
|
US5272135A
(en)
|
1991-03-01 |
1993-12-21 |
Chiron Ophthalmics, Inc. |
Method for the stabilization of methionine-containing polypeptides
|
DK36392D0
(da)
|
1992-03-19 |
1992-03-19 |
Novo Nordisk As |
Anvendelse af kemisk forbindelse
|
US5846747A
(en)
|
1992-03-25 |
1998-12-08 |
Novo Nordisk A/S |
Method for detecting glucagon-like peptide-1 antagonists and agonists
|
DK39892D0
(da)
|
1992-03-25 |
1992-03-25 |
Bernard Thorens |
Peptid
|
US5424286A
(en)
|
1993-05-24 |
1995-06-13 |
Eng; John |
Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
|
WO1995000550A1
(en)
|
1993-06-21 |
1995-01-05 |
Novo Nordisk A/S |
Aspb28 insulin crystals
|
ES2172574T5
(es)
|
1993-11-19 |
2012-11-29 |
Alkermes, Inc. |
Preparación de micropartículas biodegradables que contienen un agente biológicamente activo
|
US5705483A
(en)
|
1993-12-09 |
1998-01-06 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
US5461031A
(en)
*
|
1994-06-16 |
1995-10-24 |
Eli Lilly And Company |
Monomeric insulin analog formulations
|
DE19637230A1
(de)
|
1996-09-13 |
1998-03-19 |
Boehringer Mannheim Gmbh |
Exendin-Analoga, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
|
WO1997046584A1
(de)
|
1996-06-05 |
1997-12-11 |
Boehringer Mannheim Gmbh |
Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
|
US5948751A
(en)
*
|
1996-06-20 |
1999-09-07 |
Novo Nordisk A/S |
X14-mannitol
|
ATE208208T1
(de)
|
1996-06-20 |
2001-11-15 |
Novo Nordisk As |
Halogenid-enthaltende insulinzubereitungen
|
CN1198643C
(zh)
|
1996-06-20 |
2005-04-27 |
诺沃挪第克公司 |
含碳水化合物的胰岛素制品
|
US6110703A
(en)
|
1996-07-05 |
2000-08-29 |
Novo Nordisk A/S |
Method for the production of polypeptides
|
JP2001501593A
(ja)
|
1996-08-08 |
2001-02-06 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
胃腸運動を調節するための方法
|
US6956026B2
(en)
|
1997-01-07 |
2005-10-18 |
Amylin Pharmaceuticals, Inc. |
Use of exendins for the reduction of food intake
|
US5783556A
(en)
*
|
1996-08-13 |
1998-07-21 |
Genentech, Inc. |
Formulated insulin-containing composition
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US6006753A
(en)
|
1996-08-30 |
1999-12-28 |
Eli Lilly And Company |
Use of GLP-1 or analogs to abolish catabolic changes after surgery
|
US6277819B1
(en)
|
1996-08-30 |
2001-08-21 |
Eli Lilly And Company |
Use of GLP-1 or analogs in treatment of myocardial infarction
|
UA65549C2
(uk)
|
1996-11-05 |
2004-04-15 |
Елі Ліллі Енд Компані |
Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
|
EP0981611A1
(en)
|
1997-02-05 |
2000-03-01 |
1149336 Ontario Inc. |
Polynucleotides encoding proexendin, and methods and uses thereof
|
US5846937A
(en)
|
1997-03-03 |
1998-12-08 |
1149336 Ontario Inc. |
Method of using exendin and GLP-1 to affect the central nervous system
|
ZA984697B
(en)
|
1997-06-13 |
1999-12-01 |
Lilly Co Eli |
Stable insulin formulations.
|
EP0999853B1
(en)
|
1997-06-13 |
2003-01-02 |
Genentech, Inc. |
Stabilized antibody formulation
|
BR9811866A
(pt)
|
1997-08-08 |
2000-08-15 |
Amylin Pharmaceuticals Inc |
Compostos agonistas de exendina
|
US6444641B1
(en)
|
1997-10-24 |
2002-09-03 |
Eli Lilly Company |
Fatty acid-acylated insulin analogs
|
CA2306877A1
(en)
|
1997-10-24 |
1999-05-06 |
Eli Lilly And Company |
Insoluble insulin compositions
|
NZ504258A
(en)
|
1997-11-14 |
2002-12-20 |
Amylin Pharmaceuticals Inc |
Exendin 3 and 4 agonist compounds for the treatment of diabetes
|
DK1032587T4
(da)
|
1997-11-14 |
2013-04-08 |
Amylin Pharmaceuticals Llc |
Hidtil ukendte exendinagonist-forbindelser
|
EP1049486A4
(en)
|
1997-12-05 |
2006-01-04 |
Lilly Co Eli |
GLP-1 FORMULATIONS
|
US5981964A
(en)
|
1997-12-22 |
1999-11-09 |
Bruce J. McAuley |
Adjustable X-ray shield and on-line dosimetry system using same
|
ATE366115T1
(de)
|
1998-02-13 |
2007-07-15 |
Amylin Pharmaceuticals Inc |
Inotropische und diuretische effekte von exendin und glp-1
|
WO1999043708A1
(en)
|
1998-02-27 |
1999-09-02 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
IL138214A0
(en)
|
1998-03-09 |
2001-10-31 |
Zealand Pharmaceuticals As |
Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
DE69918070T2
(de)
|
1998-03-13 |
2005-08-25 |
Novo Nordisk A/S |
Stabilisierte, wässrige Glukagonlösungen, enthaltend Detergenzien
|
DE69939900D1
(de)
|
1998-06-05 |
2008-12-24 |
Nutrinia Ltd |
Insulin angereichertes säuglingsnährpräparat
|
WO2000020592A1
(en)
|
1998-10-07 |
2000-04-13 |
Medical College Of Georgia Research Institute, Inc. |
Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
|
US6284725B1
(en)
|
1998-10-08 |
2001-09-04 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
|
US6211144B1
(en)
*
|
1998-10-16 |
2001-04-03 |
Novo Nordisk A/S |
Stable concentrated insulin preparations for pulmonary delivery
|
US6489292B1
(en)
*
|
1998-11-18 |
2002-12-03 |
Novo Nordisk A/S |
Stable aqueous insulin preparations without phenol and cresol
|
JP2000247903A
(ja)
|
1999-03-01 |
2000-09-12 |
Chugai Pharmaceut Co Ltd |
長期安定化製剤
|
JP2007204498A
(ja)
|
1999-03-01 |
2007-08-16 |
Chugai Pharmaceut Co Ltd |
長期安定化製剤
|
US6227819B1
(en)
|
1999-03-29 |
2001-05-08 |
Walbro Corporation |
Fuel pumping assembly
|
US6271241B1
(en)
|
1999-04-02 |
2001-08-07 |
Neurogen Corporation |
Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
|
JP2002544127A
(ja)
|
1999-04-30 |
2002-12-24 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
修飾されたエキセンジンおよびエキセンジン・アゴニスト
|
ATE252601T1
(de)
|
1999-05-17 |
2003-11-15 |
Conjuchem Inc |
Lang wirkende insulinotrope peptide
|
US6344180B1
(en)
|
1999-06-15 |
2002-02-05 |
Bionebraska, Inc. |
GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
|
EP1076066A1
(en)
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
DE19947456A1
(de)
|
1999-10-02 |
2001-04-05 |
Aventis Pharma Gmbh |
C-Peptid zur verbesserten Herstellung von Insulin und Insulinanaloga
|
BR0014486A
(pt)
|
1999-10-04 |
2002-09-17 |
Chiron Corp |
Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado
|
AU2353701A
(en)
|
2000-01-11 |
2001-07-24 |
Novo Nordisk A/S |
Transepithelial delivery of glp-1 derivatives
|
US20010012829A1
(en)
|
2000-01-11 |
2001-08-09 |
Keith Anderson |
Transepithelial delivery GLP-1 derivatives
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
US6852694B2
(en)
|
2001-02-21 |
2005-02-08 |
Medtronic Minimed, Inc. |
Stabilized insulin formulations
|
DE10114178A1
(de)
|
2001-03-23 |
2002-10-10 |
Aventis Pharma Gmbh |
Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
|
DE60233722D1
(de)
|
2001-04-02 |
2009-10-29 |
Novo Nordisk As |
Insulinvorstufen und verfahren zu deren herstellung
|
AU2002318159A1
(en)
|
2001-06-29 |
2003-03-03 |
The Regents Of The University Of California |
Biodegradable/bioactive nucleus pulposus implant and method for treating degenerated intervertebral discs
|
WO2003020201A2
(en)
|
2001-08-28 |
2003-03-13 |
Eli Lilly And Company |
Pre-mixes of glp-1 and basal insulin
|
CZ2004710A3
(cs)
|
2001-12-20 |
2005-02-16 |
Eli Lilly And Company |
Inzulínová sloučenina s protrahovaným účinkem
|
AU2003203146A1
(en)
|
2002-02-07 |
2003-09-02 |
Novo Nordisk A/S |
Use of glp-1 compound for treatment of critically ill patients
|
ATE496064T1
(de)
|
2002-05-07 |
2011-02-15 |
Novo Nordisk As |
Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
|
AU2003218635A1
(en)
*
|
2002-05-07 |
2003-11-11 |
Novo Nordisk A/S |
Soluble formulations comprising insulin aspart and insulin detemir
|
DE10227232A1
(de)
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Saure Insulinzubereitungen mit verbesserter Stabilität
|
CA2490564A1
(en)
|
2002-07-04 |
2004-01-15 |
Zealand Pharma A/S |
Glp-1 and methods for treating diabetes
|
BR0314996A
(pt)
|
2002-10-02 |
2005-08-09 |
Zealand Pharma As |
Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
|
BRPI0408229A
(pt)
|
2003-03-11 |
2006-02-21 |
Novo Nordisk As |
preparação farmacêutica, métodos para preparar um ligando de ligação de zinco, para prolongar a ação de uma preparação de insulina estabilizada por ácido e para tratar diabete do tipo 1 ou tipo 2, e, uso de uma preparação
|
DE10325567B4
(de)
|
2003-06-05 |
2008-03-13 |
Mavig Gmbh |
Strahlenschutzanordnung mit separierbarer Umhüllung
|
JP5518282B2
(ja)
|
2003-09-01 |
2014-06-11 |
ノヴォ ノルディスク アー/エス |
安定なペプチドの製剤
|
TW200522976A
(en)
|
2003-09-19 |
2005-07-16 |
Novo Nordisk As |
Novel plasma protein affinity tags
|
WO2005046716A1
(en)
|
2003-11-13 |
2005-05-26 |
Novo Nordisk A/S |
Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and a insulin peptide of short time action for treatment of diabetes and bulimia
|
WO2005048950A2
(en)
|
2003-11-17 |
2005-06-02 |
Biomune, Inc. |
Tumor and infectious disease therapeutic compositions
|
US20080090753A1
(en)
|
2004-03-12 |
2008-04-17 |
Biodel, Inc. |
Rapid Acting Injectable Insulin Compositions
|
CN1960735B
(zh)
|
2004-05-20 |
2015-07-29 |
代阿麦迪卡股份有限公司 |
药物组合在治疗胰岛素抗性中的应用
|
US20060073213A1
(en)
|
2004-09-15 |
2006-04-06 |
Hotamisligil Gokhan S |
Reducing ER stress in the treatment of obesity and diabetes
|
EP1791554A2
(en)
|
2004-09-17 |
2007-06-06 |
Novo Nordisk A/S |
Pharmaceutical compositions containing insulin and insulinotropic peptide
|
JP5175103B2
(ja)
|
2004-11-12 |
2013-04-03 |
ノヴォ ノルディスク アー/エス |
安定なペプチド製剤
|
US20090011976A1
(en)
|
2004-11-12 |
2009-01-08 |
Novo Nordisk A/S |
Stable Formulations Of Peptides
|
DE102004058306A1
(de)
|
2004-12-01 |
2006-07-27 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden
|
US7957939B2
(en)
|
2005-02-01 |
2011-06-07 |
Canberra Industries, Inc. |
Maximum entropy signal detection method
|
ATE509634T1
(de)
|
2005-04-08 |
2011-06-15 |
Amylin Pharmaceuticals Inc |
Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel
|
CN101180081B
(zh)
|
2005-05-25 |
2015-08-26 |
诺沃-诺迪斯克有限公司 |
稳定的多肽制剂
|
CN101217940B
(zh)
|
2005-06-06 |
2013-03-27 |
卡穆鲁斯公司 |
Glp-1类似物制剂
|
DE102005046113A1
(de)
|
2005-09-27 |
2007-03-29 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen
|
KR101105871B1
(ko)
|
2005-09-27 |
2012-01-16 |
주식회사 엘지생명과학 |
인 난포자극호르몬의 안정한 용액 제형
|
EP1933884B1
(en)
|
2005-10-11 |
2017-09-06 |
Huntington Medical Research Institutes |
Imaging agents and methods of use thereof
|
ES2371361T3
(es)
*
|
2005-12-28 |
2011-12-30 |
Novo Nordisk A/S |
Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
|
WO2007081824A2
(en)
|
2006-01-06 |
2007-07-19 |
Case Western Reserve University |
Fibrillation resistant proteins
|
WO2007082381A1
(en)
|
2006-01-20 |
2007-07-26 |
Diamedica Inc. |
Compositions containing (s)-bethanechol and their use in the treatment of insulin resistance, type 2 diabetes, glucose intolerance and related disorders
|
US20070191271A1
(en)
|
2006-02-10 |
2007-08-16 |
Dow Pharmaceutical Sciences |
Method for stabilizing polypeptides lacking methionine
|
WO2007095288A2
(en)
|
2006-02-13 |
2007-08-23 |
Nektar Therapeutics |
Methionine-containing protein or peptide compositions and methods of making and using
|
EP2241327A1
(en)
|
2006-03-15 |
2010-10-20 |
Novo Nordisk A/S |
Mixtures of Amylin and Insulin
|
EP2004213A1
(en)
|
2006-04-03 |
2008-12-24 |
Novo Nordisk A/S |
Glp-1 peptide agonists
|
EP2015769A4
(en)
|
2006-04-13 |
2013-12-25 |
Ipsen Pharma |
PHARMACEUTICAL COMPOSITIONS OF HGLP-1, EXENDINE 4 AND THEIR ANALOGUES
|
WO2007135118A1
(en)
*
|
2006-05-24 |
2007-11-29 |
Novo Nordisk A/S |
Soluble, stable insulin-containing formulations
|
DE102006031962A1
(de)
|
2006-07-11 |
2008-01-17 |
Sanofi-Aventis Deutschland Gmbh |
Amidiertes Insulin Glargin
|
US20090318353A1
(en)
|
2006-08-25 |
2009-12-24 |
Novo Nordisk A/S |
Acylated Exendin-4 Compounds
|
CN1931360B
(zh)
*
|
2006-09-22 |
2013-02-13 |
江苏万邦生化医药股份有限公司 |
双时相精蛋白锌胰岛素注射液(30%)及其制备方法
|
EP2074141B1
(en)
|
2006-09-22 |
2016-08-10 |
Novo Nordisk A/S |
Protease resistant insulin analogues
|
WO2008124522A2
(en)
|
2007-04-04 |
2008-10-16 |
Biodel, Inc. |
Amylin formulations
|
AU2008244523B2
(en)
|
2007-04-23 |
2012-02-16 |
Intarcia Therapeutics, Inc. |
Suspension formulations of insulinotropic peptides and uses thereof
|
CN101678174A
(zh)
|
2007-06-14 |
2010-03-24 |
塞诺菲-安万特德国有限公司 |
双室卡普耳
|
ES2386166T5
(es)
|
2007-06-14 |
2016-06-21 |
Sanofi-Aventis Deutschland Gmbh |
Carpule de dos cámaras con accesorio
|
CN101366692A
(zh)
|
2007-08-15 |
2009-02-18 |
江苏豪森药业股份有限公司 |
一种稳定的艾塞那肽制剂
|
GB0717399D0
(en)
|
2007-09-07 |
2007-10-17 |
Uutech Ltd |
Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission
|
JP5551601B2
(ja)
|
2007-11-01 |
2014-07-16 |
メルク セローノ ソシエテ アノニム |
Lh液体調製物
|
JP5715418B2
(ja)
|
2007-11-08 |
2015-05-07 |
ノボ・ノルデイスク・エー/エス |
インスリン誘導体
|
JP5241849B2
(ja)
|
2007-11-16 |
2013-07-17 |
ノボ・ノルデイスク・エー/エス |
インスリン及びインスリン分泌性ペプチドを含む薬学的組成物
|
CN101444618B
(zh)
|
2007-11-26 |
2012-06-13 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
US20090186819A1
(en)
|
2007-12-11 |
2009-07-23 |
Marieve Carrier |
Formulation of insulinotropic peptide conjugates
|
NZ586589A
(en)
|
2008-01-09 |
2012-04-27 |
Sanofi Aventis Deutschland |
Novel insulin analogues having an extremely delayed time-action profile
|
RU2524423C2
(ru)
|
2008-01-09 |
2014-07-27 |
Санофи-Авентис Дойчланд Гмбх |
Новые производные инсулина с чрезвычайно замедленным профилем время/действие
|
EP2240155B1
(en)
|
2008-02-13 |
2012-06-06 |
Intarcia Therapeutics, Inc |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
TWI394580B
(zh)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
超快起作用胰島素組成物
|
US8574214B2
(en)
|
2008-08-30 |
2013-11-05 |
Sanofi-Aventis Deutschland Gmbh |
Cartridge and needle system therefor
|
JP5705115B2
(ja)
|
2008-09-10 |
2015-04-22 |
ジェネンテック, インコーポレイテッド |
蛋白質の酸化的分解の予防のための組成物および方法
|
CN101670096B
(zh)
|
2008-09-11 |
2013-01-16 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
KR101419583B1
(ko)
|
2008-10-15 |
2014-07-25 |
인타르시아 세라퓨틱스 인코포레이티드 |
고농축 약물 입자, 제형, 현탁액 및 이들의 용도
|
ES2650621T3
(es)
|
2008-10-17 |
2018-01-19 |
Sanofi-Aventis Deutschland Gmbh |
Combinación de una insulina y un agonista de GLP-1
|
JP2009091363A
(ja)
|
2008-11-21 |
2009-04-30 |
Asahi Kasei Pharma Kk |
Pthの安定化水溶液注射剤
|
CN107080836A
(zh)
|
2009-07-06 |
2017-08-22 |
赛诺菲-安万特德国有限公司 |
含有甲硫氨酸的水性胰岛素制备物
|
WO2011003823A1
(de)
|
2009-07-06 |
2011-01-13 |
Sanofi-Aventis Deutschland Gmbh |
Langsamwirkende insulinzubereitungen
|
JP2012532177A
(ja)
|
2009-07-06 |
2012-12-13 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
熱及び振動安定性インスリン製剤
|
SG178195A1
(en)
*
|
2009-07-31 |
2012-03-29 |
Sanofi Aventis Deutschland |
Long acting insulin composition
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
TWI468171B
(zh)
|
2009-11-13 |
2015-01-11 |
Sanofi Aventis Deutschland |
含glp-1激動劑及甲硫胺酸之醫藥組成物
|
PE20121362A1
(es)
|
2009-11-13 |
2012-10-17 |
Sanofi Aventis Deutschland |
Composicion farmaceutica que comprende despro36exendina-4(1-39)-lys6-nh2, insulina gly(a21)-arg(b31)-arg(b32) y metionina
|
US20110118180A1
(en)
|
2009-11-13 |
2011-05-19 |
Sanofi-Aventis Deutschland Gmbh |
Method of treatment of diabetes type 2 comprising add-on therapy to metformin
|
US20110118178A1
(en)
|
2009-11-13 |
2011-05-19 |
Sanofi-Aventis Deutschland Gmbh |
Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
EP2389945A1
(en)
|
2010-05-28 |
2011-11-30 |
Sanofi-Aventis Deutschland GmbH |
Pharmaceutical composition comprising AVE0010 and insulin glargine
|
RU2546520C2
(ru)
|
2010-08-30 |
2015-04-10 |
Санофи-Авентис Дойчланд Гмбх |
Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
|
CN103249427A
(zh)
*
|
2010-12-14 |
2013-08-14 |
诺沃—诺迪斯克有限公司 |
速效胰岛素联合长效胰岛素
|
TW201236692A
(en)
|
2011-02-02 |
2012-09-16 |
Sanofi Aventis Deutschland |
Prevention of hypoglycaemia in diabetes mellitus type 2 patients
|
US20120277147A1
(en)
|
2011-03-29 |
2012-11-01 |
Sanofi-Aventis Deutschland Gmbh |
Prevention of hypoglycaemia in diabetes mellitus type 2 patients
|
US8735349B2
(en)
|
2011-05-13 |
2014-05-27 |
Sanofi-Aventis Deutschland Gmbh |
Method for improving glucose tolerance in a diabetes type 2 patient of younger than 50 years and having postprandial plasma glucose concentration of at least 14 mmol/L
|
US20130040878A1
(en)
|
2011-05-13 |
2013-02-14 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for use in the treatment of diabetes type 2 patients
|
JP6442284B2
(ja)
|
2011-05-13 |
2018-12-19 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
2型糖尿病の処置のためのリキシセナチド及びメトホルミン
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
CN103917241A
(zh)
|
2011-08-29 |
2014-07-09 |
赛诺菲-安万特德国有限公司 |
用于2型糖尿病患者中的血糖控制的药物组合
|
WO2013050378A1
(en)
|
2011-10-04 |
2013-04-11 |
Sanofi-Aventis Deutschland Gmbh |
Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
|
US20130096060A1
(en)
|
2011-10-04 |
2013-04-18 |
Jens Stechl |
Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the pancreatic duct system
|
BR112014010200A2
(pt)
|
2011-10-28 |
2020-10-27 |
Sanofi-Aventis Deutschland Gmbh |
combinação farmacêutica, bem como seu uso na preparação de um medicamento para o tratamento de diabetes tipo 2
|
US8901484B2
(en)
|
2012-04-27 |
2014-12-02 |
Sanofi-Aventis Deutschland Gmbh |
Quantification of impurities for release testing of peptide products
|
AR092862A1
(es)
|
2012-07-25 |
2015-05-06 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
|
TWI641381B
(zh)
|
2013-02-04 |
2018-11-21 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
GB201303771D0
(en)
|
2013-03-04 |
2013-04-17 |
Midatech Ltd |
Nanoparticles peptide compositions
|
MX2016008978A
(es)
|
2014-01-09 |
2016-10-04 |
Sanofi Sa |
Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
|
SG11201604706TA
(en)
|
2014-01-09 |
2016-07-28 |
Sanofi Sa |
Stabilized pharmaceutical formulations of insulin aspart
|
RU2016132342A
(ru)
|
2014-01-09 |
2018-02-14 |
Санофи |
Стабилизированные фармацевтические составы на основе инсулиновых аналогов и/или инсулиновых производных
|